1. Overview and Epidemiology

Chagas disease, or American Trypanosomiasis, is a systemic zoonotic infection caused by the protozoan parasite Trypanosoma cruzi. While traditionally endemic to rural areas of Latin America, it has become a global health concern due to migration patterns, with significant caseloads now identified in the United States, Spain, and Canada.

It is critical to distinguish this from African Trypanosomiasis (Sleeping Sickness), caused by T. gambiense and T. rhodesiense. While both are kinetoplastid protozoa, they differ fundamentally in vector, tissue tropism, and clinical manifestation; African trypanosomiasis is characterized by CNS invasion and sleep-wake cycle disruption, whereas American trypanosomiasis primarily targets the myocardium and autonomic plexuses of the gastrointestinal tract.

2. Pathogenesis and Transmission

Vector and Transmission

The primary vector is the triatomine bug (reduviid). Unlike malaria or dengue, T. cruzi is not transmitted via the bite itself but through stercoral contamination. The bug defecates while feeding; the host then rubs the infected feces into the bite wound, mucosal membranes (conjunctiva), or skin abrasions.

Alternative transmission routes include:

• Congenital: Transplacental transmission (significant risk in endemic regions).
• Iatrogenic: Blood transfusions and organ transplantation.
• Oral: Consumption of food/juices contaminated with crushed triatomines (often leads to more severe acute phases).

Cellular Pathophysiology

Upon entry, T. cruzi transforms into amastigotes that invade host cells (myocytes, neurons, and macrophages). The pathology is driven by a combination of:

1. Direct Parasitic Destruction: Lysis of cells during the replication cycle.
2. Chronic Inflammation: A persistent, low-grade inflammatory response leading to extensive fibrosis.
3. Autonomic Denervation: Destruction of the intramural parasympathetic plexuses (Auerbach’s and Meissner’s plexuses), leading to the loss of inhibitory neurons and resulting in visceral dilation (megacolon/megaesophagus).

3. Clinical Presentation

The natural history of Chagas is divided into three distinct phases:

A. Acute Phase (Weeks to Months)

Often asymptomatic or mild, making it frequently underdiagnosed.

• Romaña’s Sign: Unilateral painless periorbital edema with conjunctivitis; highly suggestive of oral/ocular entry.
• Chagoma: An inflammatory skin nodule at the portal of entry.
• Systemic Symptoms: Low-grade fever, malaise, lymphadenopathy, and hepatosplenomegaly.
• Severe Acute Chagas: Rare but lethal; manifests as acute myocarditis or meningoencephalitis (more common in children and immunocompromised patients).

B. Indeterminate Phase (Years to Decades)

The patient is seropositive but remains asymptomatic with normal ECGs and imaging. The duration of this phase varies; some patients never progress to the chronic symptomatic stage.

C. Chronic Symptomatic Phase (Approx. 30% of infected individuals)

1. Cardiac Form (Chagasic Cardiomyopathy):

• Dilated Cardiomyopathy (DCM): Progressive biventricular failure and apical aneurysm formation (pathognomonic).
• Conduction System Disease: Right Bundle Branch Block (RBBB) is the most common ECG finding, often accompanied by Left Anterior Fascicular Block (LAFB).
• Arrhythmias: High risk of ventricular tachycardia and sudden cardiac death.
• Thromboembolism: Stasis in dilated chambers increases the risk of systemic embolism/stroke.

2. Digestive Form (Visceral Megasyndromes):

• Megaesophagus: Achalasia-like presentation; dysphagia, regurgitation, and aspiration pneumonia due to loss of lower esophageal sphincter relaxation.
• Megacolon: Severe chronic constipation, fecaloma formation, and risk of sigmoid volvulus.

4. Diagnostic Algorithm

Diagnosis is phase-dependent:

Acute Phase (High Parasitemia)

• Direct Microscopy: Fresh blood films or concentrated thick smears (strout method) to visualize motile trypomastigotes.
• PCR: Highly sensitive and specific for detecting parasite DNA in the early stage.

Chronic Phase (Low/Intermittent Parasitemia)

Parasites are rarely found in peripheral blood; diagnosis relies on serology.

• Serological Testing: Due to potential cross-reactivity with other kinetoplastids, two different serological tests (e.g., ELISA and Indirect Immunofluorescence/IHA) are required for a definitive diagnosis. If results are discordant, a third test is performed.

5. Therapeutic Management

Antiparasitic Therapy

The goal is to eliminate the parasite and prevent progression to chronic disease.

• First-line Agents: Benznidazole (preferred) and Nifurtimox.
• Indications: Mandatory for all acute cases, congenital infections, and children/adolescents in the indeterminate phase.
• Chronic Phase Controversy: The BENEFIT trial suggested limited benefit of Benznidazole in reducing cardiac morbidity in advanced chronic cardiomyopathy; however, treatment is still considered for those in the indeterminate phase to prevent progression.
• Side Effects: Be vigilant for severe dermatitis (hypersensitivity), peripheral neuropathy, and bone marrow suppression.

Management of Complications

• Heart Failure: Standard Guideline-Directed Medical Therapy (GDMT)—ACE inhibitors, Beta-blockers, and diuretics.
• Arrhythmias/SCD: Implantable Cardioverter Defibrillators (ICDs) for patients with high risk of sudden cardiac death or severe ventricular arrhythmias.
• Digestive Issues: Prokinetics, dietary modifications, and surgical interventions (e.g., Heller myotomy for esophagus or surgical resection for megacolon).

6. Special Considerations: HIV Co-infection

In severely immunocompromised patients (CD4 < 200 cells/mm³), T. cruzi can reactivate. This may present as Chagasic encephalopathy, characterized by brain abscesses or space-occupying lesions that mimic Toxoplasmosis or Primary CNS Lymphoma. MRI and PCR of the CSF are essential for diagnosis.

7. Prevention and Public Health

• Vector Control: Indoor residual spraying with pyrethroids to eliminate triatomines from dwellings.
• Housing Improvement: Replacing mud walls/thatch roofs (where bugs reside) with plastered walls and metal roofs.
• Screening: Mandatory screening of blood donors and organ procurement in endemic areas to prevent iatrogenic transmission.
• Prenatal Screening: Screening pregnant women in endemic zones to allow for early treatment of newborns, where cure rates are highest.